<DOC>
	<DOCNO>NCT00772382</DOCNO>
	<brief_summary>The primary objective study demonstrate long-term safety tolerability MCI-196 subject stage V chronic kidney disease dialysis hyperphosphatemia . The secondary objective study ass long-term efficacy flexible dose MCI-196 .</brief_summary>
	<brief_title>Study MCI-196 Chronic Kidney Disease Stage V Subjects Dialysis With Hyperphosphatemia</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Hyperphosphatemia</mesh_term>
	<mesh_term>Bile Acids Salts</mesh_term>
	<criteria>Male female , &gt; =18 year old Stable hemodialysis peritoneal dialysis Subjects stable phosphate control Subjects stabilize phosphorus diet Subjects undergo regular dialysis treatment Females childbearing potential negative serum pregnancy test Male subject must agree use appropriate contraception Current clinically significant medical comorbidities , may substantially compromise subject safety , expose him/her undue risk , interfere significantly study procedure , opinion Investigator , make subject unsuitable inclusion study serum albumin level &lt; 3.0g/L PTH level &gt; 1000pg/mL Hemoglobin level &lt; 8mg/dL A History significant gastrointestinal motility problem Biliary obstruction proven liver dysfunction A positive test HIV 1 2 antibody A history substance alcohol abuse within last year Seizure disorder A history drug allergy use cholestyramine , colestipol colesevelam Schedule receive kidney transplant within next 6 month Participation clinical study experimental medication last 30 day experimental biological product within last 90 day prior sign inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Chronic Kidney Disease</keyword>
	<keyword>Dialysis</keyword>
	<keyword>Hyperphosphatemia</keyword>
	<keyword>Phosphate binder</keyword>
</DOC>